Ability of a Molecule (Prima) to Restore Physiological Differentiation in Epithelium Expressing Gene p63
NCT ID: NCT02896387
Last Updated: 2022-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
5 participants
OBSERVATIONAL
2017-03-03
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
P63 gene belongs to the family of p53 gene. The functions of the two proteins are very similar. Data suggest that molecule Prima could reactivate the p63 protein mutated in patients and thus alleviate skin defect healing and limbic regeneration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation
NCT06706388
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
NCT06789913
Development of In Vitro Functional Assays From Primary Cells of Patients With Monogenic Diseases
NCT03763864
MPS (RaDiCo Cohort) (RaDiCo-MPS)
NCT06036693
Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
NCT02638389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 7 years
Exclusion Criteria
* low vision mostly related to retinal pathology
* Pregnant or breast-feeding patient
7 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric GABISON
Role: PRINCIPAL_INVESTIGATOR
Fondation ophtalmologique de Rothschild
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondation Opthalmologique A de Rothschild
Paris, , France
Hopital Necker
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EGN_2016_14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.